Alkermes plc (F:8AK) — Market Cap & Net Worth
Market Cap & Net Worth: Alkermes plc (8AK)
Alkermes plc (F:8AK) has a market capitalization of $6.65 Billion (€5.69 Billion) as of September 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #2968 globally and #584 in its home market, demonstrating a -0.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alkermes plc's stock price €38.98 by its total outstanding shares 167763272 (167.76 Million). Also see Alkermes plc balance sheet assets for a full breakdown of the balance sheet.
Alkermes plc Market Cap History: 2026 to 2026
Alkermes plc's market capitalization history from 2026 to 2026. Data shows growth from $7.65 Billion to $7.65 Billion (0.00% CAGR). Also see 8AK cash flow metrics for how efficiently the company converts equity into cash flow.
Alkermes plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alkermes plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Alkermes plc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8AK by Market Capitalization
Companies near Alkermes plc in the global market cap rankings as of September 16, 2026. Review Alkermes plc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Alkermes plc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Alkermes plc Historical Marketcap From 2026 to 2026
Between 2026 and today, Alkermes plc's market cap moved from $7.65 Billion to $ 7.65 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Alkermes plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.65 Billion USD |
| MoneyControl | $6.65 Billion USD |
| MarketWatch | $6.65 Billion USD |
| marketcap.company | $6.65 Billion USD |
| Reuters | $6.65 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more